-
41.
公开(公告)号:US20240059665A1
公开(公告)日:2024-02-22
申请号:US18267331
申请日:2021-12-16
申请人: UCB Biopharma SRL
发明人: Claude Delatour
IPC分类号: C07D401/06
CPC分类号: C07D401/06
摘要: The present invention relates to compound according to formula (I) which is a positive allosteric modulator of D1 and accordingly of benefit as pharmaceutical agent for the treatment of diseases in which D1 receptors play a role.
-
公开(公告)号:US11905310B2
公开(公告)日:2024-02-20
申请号:US17327865
申请日:2021-05-24
申请人: UCB BIOPHARMA SRL
发明人: Michael Harry Rose
摘要: The present invention relates to a process for purification a protein comprising a semi-continuous chromatography step whereby the flow-through is collected and re-loaded onto the chromatography matrix.
-
公开(公告)号:US20240000719A1
公开(公告)日:2024-01-04
申请号:US18039498
申请日:2021-11-29
申请人: UCB BIOPHARMA SRL
CPC分类号: A61K9/70 , A61K47/26 , A61K9/146 , A61K47/10 , A61K47/34 , A61K47/183 , A61K9/19 , A61K9/0024 , B33Y70/00
摘要: The invention relates to the field of pharmaceutical compositions comprising proteins as therapeutic agents. More particularly, it is directed to hot melt extrusion-produced antibody-containing filaments, implantable drug delivery devices made from these filaments and to methods of producing such filaments and devices. The hot melt extrusion-produced antibody-containing filaments and the devices obtained from the filaments according to the invention allow the delivery of the antibody over a certain period of time.
-
公开(公告)号:US20230416357A1
公开(公告)日:2023-12-28
申请号:US18253240
申请日:2021-12-06
申请人: UCB BIOPHARMA SRL
发明人: Joseph Michael David RASTRICK , John Paul SILVA , Kerry Louise TYSON , Peter Charles ELLIOTT , Seppe Frans Roman LEYSEN , Zainab AHDASH
IPC分类号: C07K16/24
CPC分类号: C07K16/244 , C07K2317/76 , C07K2317/92 , C07K2317/34 , C07K2317/24 , C07K2317/55 , C07K2317/33
摘要: The present invention relates to antibodies binding to IL22 and inhibiting its interaction with one or more of its natural ligands Specific examples of such antibodies are provided. The therapeutic uses of the antibodies and methods of generating such C are also provided.
-
公开(公告)号:US11786593B2
公开(公告)日:2023-10-17
申请号:US17078127
申请日:2020-10-23
申请人: UCB BIOPHARMA SRL
IPC分类号: A61K39/395 , C07K1/113 , C07K16/28 , C07K16/18 , C07K5/12 , C07C323/12 , C07C323/25
CPC分类号: A61K39/39591 , C07K1/1133 , C07K1/1136 , C07K16/18 , C07K16/2878 , C07C323/12 , C07C323/25 , C07K5/123 , C07K2317/31
摘要: The present invention provides method of increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises: a) a conversion step of treating the composition with a denaturant selected from urea and/or Guanidine hydrochloride; b) wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.
-
46.
公开(公告)号:US20230295657A1
公开(公告)日:2023-09-21
申请号:US18021005
申请日:2021-08-11
申请人: UCB BIOPHARMA SRL
发明人: NIKITA DALAL , AMI KABADI , TOSHAL ROHIT PATEL , PATRICK MARK DOWNEY , AMULYA NIDHI SHRIVASTAVA
CPC分类号: C12N15/86 , C07K14/4702 , A61K48/0066 , C12N2750/14143 , C12N2830/008
摘要: The present invention relates to nucleic acid constructs comprising methyl CpG binding protein 2 (MeCP2) promoter sequences. The present invention further relates to vectors, viral vector host cells and pharmaceutical compositions comprising said nucleic acid constructs. The present invention also concerns the therapeutic use of said nucleic acid constructs, vectors, viral vectors and pharmaceutical compositions.
-
公开(公告)号:US20230287100A1
公开(公告)日:2023-09-14
申请号:US18045623
申请日:2022-10-11
申请人: UCB BIOPHARMA SRL
发明人: Sophie Glatt , Lucian Ionescu , Margaret Jones , Ruth Oliver , Stevan Graham Shaw , Foteini Strimenopoulou , Venkata Pavan Kumar Vajjah
CPC分类号: C07K16/244 , A61P17/06 , A61P19/02 , A61K2039/505
摘要: The invention relates to therapeutic uses of antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F in the treatment of dermatological and rheumatological diseases, such as psoriasis, psoriatic arthritis and axial spondyloarthritis.
-
公开(公告)号:US20230271951A1
公开(公告)日:2023-08-31
申请号:US17995495
申请日:2021-04-06
申请人: UCB BIOPHARMA SRL
发明人: Prafulkumar Tulshibhai CHOVATIA , Anne Marie FOLEY , Gregory William HASLETT , Martin Clive HUTCHINGS , James Andrew JOHNSON , Fabien Claude LECOMTE , Nathaniel Julius Thomas MONCK , Joanna Rachel QUINCEY , Konstantinos RAMPALAKOS , James Thomas REUBERSON , Adam Peter SMALLEY , Giancarlo TRANI , Darshan Gunvant VAIDYA
IPC分类号: C07D413/14 , A61K45/06 , C07D403/14 , C07D413/12 , C07D471/04 , C07D235/24 , C07D403/12
CPC分类号: C07D413/14 , A61K45/06 , C07D235/24 , C07D403/12 , C07D403/14 , C07D413/12 , C07D471/04
摘要: A series of substituted 4,4-difluorocyclohexyl derivatives as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
-
公开(公告)号:US11674967B2
公开(公告)日:2023-06-13
申请号:US17013326
申请日:2020-09-04
申请人: UCB BIOPHARMA SRL
发明人: James Philip O'Connell , John Robert Porter , Alastair Lawson , Boris Kroeplien , Stephen Edward Rapecki , Timothy John Norman , Graham John Warrellow , Tracy Lynn Arakaki , Alex Buntin Burgin , William Ross Pitt , Mark Daniel Calmiano , David Andreas Schubert , Daniel John Lightwood , Rebecca Jayne Munro
IPC分类号: G01N33/68 , C07D401/14 , C07K14/525 , C07D471/00 , C07K14/705 , C07K16/24 , C07D213/72 , C07D235/04 , C07D239/26 , C07D471/04 , A61K47/64 , A61P37/00 , A61P35/00
CPC分类号: G01N33/6845 , A61K47/6425 , A61P35/00 , A61P37/00 , C07D213/72 , C07D235/04 , C07D239/26 , C07D401/14 , C07D471/00 , C07D471/04 , C07K14/525 , C07K14/70575 , C07K16/241 , G01N33/6854 , G01N33/6863 , C07K2317/55 , C07K2317/92 , G01N2333/525 , G01N2500/02
摘要: A new, stable trimeric TNFα structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNFα/TNFR1 interaction. Membrane-bound TNFα is not affected in its ability to signal through TNFR2, and thus the new structure of TNFα may be used in therapies which do not significantly raise the risk of infection or malignancy.
-
公开(公告)号:US20230176071A1
公开(公告)日:2023-06-08
申请号:US17923904
申请日:2021-05-06
申请人: UCB BIOPHARMA SRL
发明人: Anastasios SPILIOTOPOULOS , David James MCMILLAN , Michael John Wright , Sebastian KELM , Xiaofeng LIU , Daniel John LIGHTWOOD
IPC分类号: G01N33/68
CPC分类号: G01N33/6857
摘要: A method of identifying of amino-acid residues on a target protein that form a binding site of a molecule of interest. Such method relies on selection of relevant patches of solvent-accessible residues and testing of an array of mutated proteins for changes of binding properties. Such method is useful for determining binding sites (epitopes) of antibodies, ligands and related molecules.
-
-
-
-
-
-
-
-
-